The Manufacturability Gap
New therapies are failing in manufacturing — not in the lab. Fragile modalities. Viscous formulations. Unstable TMP. Scale-up failure. Alphinity designs the fluid handling systems that solve these problems at the source.
Enabling Abundance in Medicine™ — precision fluid handling for the therapies that matter most
Process-First Engineering
Every piece of Alphinity equipment is designed around a specific process challenge. Four territories where conventional fluid handling consistently fails — and where our technology makes the difference.
Viral vectors, cell therapies, exosomes, LNPs. Standard processing loses 20–40% of AAV titer to mechanical damage. Our single-use diaphragm pump eliminates the root cause — positive displacement with no product contact with moving parts.
High-concentration mAbs, dense biologics, viscous buffers, and intensified processes. Conventional pumping technologies cannot maintain reliable flow above ~500 cP. Our diaphragm pump handles up to 3,000 cP with flow rate independent of viscosity and backpressure.
Unstable transmembrane pressure leads to membrane fouling, inconsistent flux, and failed batches. Near-pulseless diaphragm pumping combined with our electric diaphragm valve delivers the precision-controlled flow that sensitive processes demand.
Processes that work at bench scale fail in manufacturing because the mechanical conditions change with scale. Alphinity's platform maintains identical flow behaviour from 30 mL screening to 10 L clinical batches — no process redesign.
The physics of the problem
Standard bioprocess fluid handling was engineered for water, not biologics. The mechanical limitations of legacy pumping technologies — compression, cavitation, pulsation, particle shedding — are not design oversights. They are the unavoidable consequence of how these technologies function. Eliminating them requires a fundamentally different architecture.
| Process Challenge | Conventional Equipment | Alphinity Platform |
|---|---|---|
| Shear damage | ✕High — roller compression every revolution | ✓Ultra-low — no product contact with moving parts |
| AAV / LV titer loss | ✕20–40% product lost to pump-induced damage | ✓4.4× better filterability vs low-shear benchmarks |
| Viscous formulations | ✕Fails above ~500 cP; flow drops with viscosity | ✓Handles up to 3,000 cP; flow independent of viscosity |
| Pressure control | ✕Pneumatic valves require compressed air infrastructure | ✓24V DC electric — ±0.3 PSI accuracy, no compressed air |
| Scale-up continuity | ✕Different equipment at each scale — process redesign required | ✓Same architecture from 30 mL screening to 10 L clinical |
| TMP stability | ✕One pressure spike per roller pass — membrane fouling | ✓Near-pulseless — stable TMP, consistent flux |
Our solutions
Each product solves a specific manufacturing problem. They work independently — and together as an integrated platform.
Launching at Interphex 2026
Tangential flow filtration for sensitive biologics. Ultra-low shear pumping. 30 mL to 10 L. Fully automated.
Pump Technology
Positive displacement. Ultra-low shear, near-pulseless flow. Handles viscous fluids where peristaltic pumps fail.
Valve Technology
±0.3 PSI precision, continuously adjustable via microstepping. 24V DC electric — no compressed air required.
Pinch Valve Series
Motorized, pneumatic, and manual pinch valves. Clamp-on design, visible position indicator, compatible with all standard single-use tubing.
Page coming soon
Process Safety
Prevents backflow and protects process integrity. Available in multiple port configurations for inline integration across tubing sizes.
Page coming soon
Process Expertise
Most bioprocess problems are blamed on chemistry — buffer formulation, cell line, upstream conditions. In our experience, the failure is often mechanical. The physics of how fluid is moved matters as much as what's in it.
Understanding the failure modes is how we design equipment that doesn't cause them.
Most bioprocess pumping technology was engineered for water and chemical transfer — not sensitive biologics. The mechanical principles that make them work (compression, rotor contact, pulsation) are fundamentally incompatible with fragile proteins and viral particles. The damage is cumulative, often invisible, and inherent to the design — not a flaw that can be tuned away.
When a pump creates negative pressure at its inlet, dissolved gases form bubbles that collapse violently — generating forces that destroy proteins and viral particles at the molecular level.
Because the mechanical conditions change. Different pump, different flow profile, different pressure dynamics. Physical process continuity matters as much as the recipe.
Bespoke Systems
Standard systems force your process to adapt to the equipment. We start with your process constraints — flow behaviour, pressure sensitivity, viscosity, scale — and engineer a system that fits. PIXER® pumps, VannX™ valves, and ConSynSys™ automation as building blocks.
Built to the standards that matter
In the industry
Alphinity is active across the global bioprocessing community — at the conferences where the industry's process challenges are discussed and solved.
April 21–23, 2026
See TFFi™ live. Booth 1361, Javits Convention Center.
Book a demo →
September 15, 2026 · Leiden, Netherlands
Corpus Congress Centre, Leiden.
October 7, 2026 · Foxborough, MA
Gillette Stadium, Foxborough.
Get Started
Start with a datasheet, or talk directly to our process engineers. We'll help you find the right approach for your application.